|Within your trust how many intra-vitreal vials/implants have been used in the latest 4 months, if possible between May and August 2017?|
|Please state the number of vials dispensed from your pharmacy in this period, if the number for wet AMD is not known, then regardless of reason for use.|
|Lucentis (ranibizumab) Injections||Avastin (bevacizumab) Injections||Eylea (aflibercept) Injections||Illuvien (Fluocinolone) Impants||Ozudex (Dexamethasone) Implants|
|Total Vials / Implants|
|Vials / Impants for Wet Age Related Macular Degeneration (wAMD)|
The information requested above has been repeatedly asked for in total 4 times – for your information attached in date order, together with relevant links to where they are published:
The most recent request 4128 2017 has been published here:
The latest request has been considered and has been deemed vexatious under Section 14(1) for the Freedom of Information Act 2000.
The Information Commissioner recognises that dealing with the unreasonable requests can place a strain on resources and get in the way of delivering mainstream services or answering legitimate requests. Section 14 (1) is designed to protect public authorities by allowing them to refuse any requests which have the potential to cause disproportionate or unjustified level of disruption, irritation or distress.
A request which would not normally be regarded as vexatious in isolation may assume that quality once considered in context. Submitting frequent repeat requests that have been answered and published previously places a strain on the Trust resources, and the most recent request is contributing to that aggregated burden.